Multimodal treatment of patients with minor salivary gland cancer in the case of recurrent disease.
BACKGROUND
Our aim in this study was to identify prognostic factors and the optimal therapeutic management in patients with minor salivary gland carcinomas.


METHODS
Overall and disease-free survival and overall survival after recurrence in patients with adenoidcystic carcinoma (n = 25), mucoepidermoid carcinoma (n = 8), adenocarcinoma (n = 5), carcinoma ex pleomorphic adenoma (n = 4), and others (n = 5) were correlated to clinical data.


RESULTS
Overall survival correlated to treatment modality (p = .039) and T classification (p = .003), whereas prolonged disease-free interval correlated to treatment (p < .001) and T classification (p = .009). Overall survival after recurrence correlated to treatment of recurrence (p = .006) and initial T classification (p = .02). Multivariate analysis showed that overall survival after recurrence correlated to treatment of recurrence (p = .019) and initial T classification (p = 0.019). T classification was a prognostic factor for overall survival (p = .002) and disease-free interval (p = .002).


CONCLUSIONS
The initial tumor classification is a clinical predictor for patients' overall and disease-free survival and overall survival after recurrence. Multimodal treatment significantly improves patients' overall survival.
Erovic
Boban M
BM
Department of Otorhinolaryngology, Head and Neck Surgery, Medical University of Vienna, Vienna, Austria.
Schopper
Christian
C
Pammer
Johannes
J
Vormittag
Laurenz
L
Maleki
Amir
A
Brunner
Markus
M
Heiduschka
Gregor
G
Grasl
Matthaeus Ch
MCh
Thurnher
Dietmar
D
D008949:Adenoma, Pleomorphic / Q000401:mortality / Q000473:pathology / Q000628:therapy; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D003528:Carcinoma, Adenoid Cystic / Q000401:mortality / Q000473:pathology / Q000628:therapy; D018277:Carcinoma, Mucoepidermoid / Q000401:mortality / Q000473:pathology / Q000628:therapy; D017024:Chemotherapy, Adjuvant; D015331:Cohort Studies; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D009364:Neoplasm Recurrence, Local / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D009367:Neoplasm Staging; D016016:Proportional Hazards Models; D018714:Radiotherapy, Adjuvant; D012189:Retrospective Studies; D012468:Salivary Gland Neoplasms / Q000401:mortality* / Q000473:pathology / Q000628:therapy*; D012470:Salivary Glands, Minor / Q000473:pathology* / Q000601:surgery; D016019:Survival Analysis; D016896:Treatment Outcome